Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 6/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028359 | 1.00 | CHRNA3 (0.39) | CHRNA3CHRNB4HRH3CHRNB2CHRNA4 | |
| SCHEMBL20028808 | 1.00 | CHRNA3 (0.39) | CHRNA3CHRNB4HRH3CHRNB2CHRNA4 | |
| SCHEMBL12213043 | 0.94 | HRH3 (0.43) | CHRNA3CHRNB4HRH3FDPS | |
| SCHEMBL10103537 | 0.88 | — | — | |
| SCHEMBL3349213 | 0.82 | FDPS (0.42) | CHRNA3CHRNB4HRH3FDPS | |
| SCHEMBL14043157 | 0.82 | FDPS (0.42) | CHRNA3CHRNB4HRH3FDPS | |
| SCHEMBL593996 | 0.81 | CHRNA3 (0.37) | CHRNA3CHRNB4HRH3CHRNB2CHRNA4 | |
| SCHEMBL593510 | 0.81 | CHRNA3 (0.37) | CHRNA3CHRNB4HRH3CHRNB2CHRNA4 | |
| SCHEMBL6978705 | 0.80 | CYP2D6 (0.44) | CHRNA3CHRNB4HRH3FDPS | |
| Hydrochloric Acid SCHEMBL3347358 | 0.80 | KMT2A (0.41) | CHRNA3CHRNB4HRH3FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2019074809-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | CHRNA3 3998/4885CHRNB4 3911/4885HRH3 2154/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | CHRNA3 2784/4885CHRNB4 3427/4885HRH3 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.